KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML ...

Nuvation Bio , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of its license agreement for VEPPANUTM ...

ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m or ...

The National Association of Women in Construction Las Vegas recently launched a new scholarship in partnership with trade ...

High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, ...

Veloxis Pharmaceuticals, Inc. (Veloxis), a global specialty pharmaceutical company part of Asahi Kasei Corporation, which is committed to improving the lives of transplant and other immunocompromised ...

“The Year 2 jump” is practically cliché in NFL circles. The Packers’ season might depend on Matthew Golden becoming a star in ...

Patients who need repeated MRI scans with contrast dye could soon receive a fraction of the gadolinium they currently get.

Background Psoriatic arthritis (PsA) is a chronic inflammatory systemic disease that is associated with cardiovascular ...

A 70-year-old woman presents to the ED with chest pain, shortness of breath and diaphoresis. Her symptoms began about 24 ...

- 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial - - 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML - - ...